Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Based on feedback from FDA

Conditions

Essential Fatty Acid Deficiency (EFAD)

Interventions

DRUG: Clinolipid
DRUG: Intralipid

Sponsor

Baxter Healthcare Corporation